Rapid cost-effective species ID & AMR test for STI

Our robust and user-friendly rapid PCR platform with the cost-effective single use test cartridges deliver results for up to 25 targets in under 30 min and enable evidence-based treatment during the initial consultation.

Our rapid low barrier diagnostic platform enables resistance guided treatment during the initial consultation. The cost effective and user friendly platform provides access to patient centered treatment for more people and helps to eliminate empiric broad spectrum antimicrobial use especially in economically constrained settings.

  • Antimicrobial stewardship
  • Microbial diagnostics
  • Infection prevention
  • Antimicrobial compound/strategy
  • Removal antibiotics/bacteria

  • Bacteria
  • Viruses
  • Fungi
  • Yeasts
  • Parasites

  • Human
  • Veterinary
  • AgriFood
  • Environmental
  • Other

Development stage:
  • Development
  • Research
  • Validation
  • Market entry
  • Marketed product

  • Company
  • Academia
  • Institute
  • NGO
  • Government

  • Co-develop
  • Joint Venture
  • Sell
  • License
  • Outsource

Funding organisation:
  • OTHER / NA
  • CARB-X
  • FIND

Infectious disease area:
  • STI
  • RTI
  • UTI
  • BSI
  • GII
  • SSTI
  • CNSI
  • IAI
  • SSI

Geographic origin:
  • Eurasia
  • North America
  • South America
  • Africa
  • Oceania

AMR target validation strategies; Broaden our Investor base; Test portfolio development; Distribution and market entry partnerships

Sefunda is a lean team of 6 scientists and engineers on a mission to make rapid PCR testing an accessible standard for everybody. To date most infectious diseases are treated empirically with broad-spectrum antibiotics covering multiple possible pathogens. The gold standard for evidence-based targeted treatment is elaborate lab testing including molecular testing and microbiological culture, which is costly and time consuming. Sefunda takes up the banner to democratize patient tailored medicine by filling a blank between cost prohibitive lab workup and empiric treatment. We are developing a fully integrated rapid PCR platform delivering just the right amount of actionable information on the spot. Our advanced sample to answer prototype is currently under internal pre-validation and delivers lab quality PCR results for up to 25 molecular targets in under 30 minutes. Our first test detects sexually transmitted diseases with antimicrobial resistance markers.

We are developing a user-friendly diagnostic platform with cost-effective single use test cartridges for multiple test indications, all with a focus on improving patient management and antimicrobial stewardship.

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed